drugset / Trial / NCT00211393
A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole
Phase 2
Completed
5 enrolled
Manhattan Eye, Ear & Throat Hospital
LuEsther T. Mertz Retinal Research Center · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the effect of an adrenocorticoid antagonist (ketoconazole), 600 mg per day for 4 weeks, in the treatment of patients with central serous chorioretinopathy (CSC).
Timeline
- Start
- 2005-05
- Primary completion
- 2008-03
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketoconazole | Small molecule | 600 mg | Oral |